The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Tariot, Pierre N.; Lopera, Francisco; Langbaum, Jessica B.; Thomas, Ronald G.; Hendrix, Suzanne; Schneider, Lon S.; Rios‐Romenets, Silvia; Giraldo, Margarita; Acosta, Natalia; Tobon, Carlos; Ramos, Claudia; Espinosa, Alejandro; Cho, William; Ward, Michael; Clayton, David; Friesenhahn, Michael; Mackey, Howard; Honigberg, Lee; Sanabria Bohorquez, Sandra; Chen, Kewei; Walsh, Trisha; Langlois, Carolyn; Reiman, Eric M.; Alzheimer's Prevention Initiative

doi:10.1016/j.trci.2018.02.002

Cited by 128Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Open access

Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios‐Romenets, Silvia, Giraldo, Margarita +16 more·2018·Alzheimer's & Dementia: Translational Research & Clinical Interventions

DOI 10.1016/j.trci.2018.02.002PMC PMC6021543

Open this paper in CoChat — free account Open PDF

Abstract

Introduction: Autosomal‐dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have “preclinical” AD. Crenezumab is an antiamyloid monoclonal antibody that binds monomeric and aggregated forms of amyloid β, with highest affinity for oligomers; it is in development for early stages of sporadic AD and for ADAD. Methods: This is a prospective, randomized, double‐blind, placebo‐controlled phase 2 study of the efficacy of crenezumab versus placebo in asymptomatic PSEN1 E280A mutation carriers from family kindreds with ADAD in Colombia. Participants were randomized to receive either crenezumab or placebo for 260 weeks. The study was designed to enroll a planned total of 300 participants, including 200 preclinical mutation carriers (approximately 100 treatment, 100 placebo) and an additional control group of mutation noncarriers from the same family kindreds included to mask mutation carrier status (100 placebo only). The primary outcome is change in the Alzheimer's Prevention Initiative ADAD Composite Cognitive Test Score from baseline to week 260. Secondary outcomes include time to progression to mild cognitive impairment due to AD or dementia due to AD; changes in dementia severity, memory, and overall neurocognitive functioning; and changes in amyloid–positron emission tomography, fluorodeoxyglucose–positron emission tomography, magnetic resonance imaging volumes, and cerebrospinal fluid levels of β amyloid, tau, and p‐tau. Safety and tolerability are assessed. Results: Two hundred fifty‐two participants were enrolled between December 2013 and February 2017. Discussion: We describe the first large‐scale, potentially label‐enabling clinical trial of a preclinical treatment for ADAD. Results from this trial will inform on the efficacy of crenezumab for delaying onset of, slowing decline in, or preventing cognitive impairment in individuals with preclinical ADAD and will foster an improved understanding of AD biomarkers and their relationship to clinical outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.trci.2018.02.002

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Crenezumab is being used in the API ADAD Colombia trial of known mutation carriers.
“Crenezumab is being used in the API ADAD Colombia trial of known mutation carriers (Tariot et al., 2018), whereas active immunization with CAD106 is being used in the API Generation trial of APOE ε4 homozygotes (Lopez Lopez et al., 2019).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Tariot et al., 2018

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010 · see citing works
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,803 · see citing works
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,003 · see citing works
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 3× · see citing works
“An independent data monitoring committee that includes a representative from the National Institute on Aging (NIA) oversees safety data and will be Table 3 Schedule of assessments (abridged) Time point Screening Baseline (W1) Q2 weeks after BL W4 Q12 weeks after BL up to W52 W16 W26 W38 W52 Q26 weeks after W52 W104 W2…”
MethodInfluential
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · see citing works
Untitled work
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236 · see citing works
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Self-citation
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · see citing works
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,756 · see citing works
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175 · see citing works
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130 · see citing works
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,630 · see citing works
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · see citing works
The Neuropsychiatric Inventory
Cummings, J. L. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.10s · Cited by 2,017 · see citing works
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,774 · see citing works
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,627 · see citing works
Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · see citing works
Genuine memory deficits in dementia
Grober, E. H., & Herman Buschke, L. (1987) · Developmental Neuropsychology · doi:10.1080/87565648709540361 · Cited by 1,045 · see citing works
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038 · see citing works
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · see citing works
Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs
Mohs, R. C., Knopman, D. S., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L. A., Geldmacher, D., Clark, C. M., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 693 · see citing works
Raven Progressive Matrices
Raven, J. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0153-4_11 · Cited by 637 · see citing works
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599 · see citing works
Functional Assessment Staging (FAST) in Alzheimer’s Disease: Reliability, Validity, and Ordinality
Sclan, S. G., & Reisberg, ‌. (1992) · International Psychogeriatrics · doi:10.1017/s1041610292001157 · Cited by 596 · see citing works
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works
Self-ratings of spoken language dominance: A Multilingual Naming Test (MINT) and preliminary norms for young and aging Spanish–English bilinguals
Gollan, T. H., Weissberger, G. H., Runnqvist, E., Montoya, R. I., & CERA, C. M. (2011) · Bilingualism Language and Cognition · doi:10.1017/s1366728911000332 · Cited by 536 · see citing works
Dementia incidence continues to increase with age in the oldest old: The 90+ study
Corrada, M. M., Brookmeyer, R., Paganini‐Hill, A., Berlau, D., & Kawas, C. H. (2010) · Annals of Neurology · doi:10.1002/ana.21915 · Cited by 523 · see citing works
An analysis of certain psychological tests used for the evaluation of brain injury.
Armitage, S. G. (1946) · The Psychological Monographs · doi:10.1037/h0093567 · Cited by 518 · see citing works
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.
Mohs, R. C., Knopman, D. S., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L. A., Geldmacher, D., Clark, C., et al. (1997) · PubMed · Cited by 487 · see citing works
Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation
Lopera, F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340027028 · Cited by 351 · see citing works
Self-citation
An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317 · see citing works
Self-citation
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study
Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70323-9 · Cited by 263 · see citing works
Self-citation
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation
Lopera, F. J. (1997) · JAMA · doi:10.1001/jama.277.10.793 · Cited by 255 · see citing works
Self-citation
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study
Fleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242 · see citing works
Self-citation
Clinical Gerontology: A Guide to Assessment and Intervention Clinical Gerontology: A Guide to Assessment and Intervention BrinkT. L., PhD, Editor (1986). The Haworth Press, 28 East 22nd Street, New York, NY 10010. 517 pp. $49.95.
Meaker, M. K. (1987) · American Journal of Occupational Therapy · doi:10.5014/ajot.41.4.269b · Cited by 213 · see citing works
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup
Sperling, R. A., Aisen, P. S. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J. A., Montine, T. J., et al. (2011) · Cited by 197 · see citing works
Self-citation
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
Kozauer, N., & Katz, R. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302513 · Cited by 193 · see citing works
Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice
Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., Ronan, V., Symmonds, K., Gordon, M. N., & Morgan, D. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0695-06.2006 · Cited by 154 · see citing works
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease
Langbaum, J. B. S., Hendrix, S. B., Ayutyanont, N., Chen, K., Fleisher, A., Shah, R. C., Barnes, L. L., Bennett, D. A., Tariot, P. N., & Reiman, E. M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.002 · Cited by 128 · see citing works
Self-citation
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., Pfeifer, A., Pihlgren, M., Bainbridge, T. W., Reichelt, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39374 · Cited by 124 · see citing works
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B. S., Tariot, P. N., Lopera, F. J., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 91 · see citing works
Self-citation
Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease
Sepulveda‐Falla, D., Matschke, J., Bernreuther, C., Hagel, C., Puig, B., Villegas, A., Garcia, G., Zea, J., Gomez‐Mancilla, B., Ferrer, I., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00469.x · Cited by 82 · see citing works
Self-citation
The Alzheimer’s Prevention Initiative Composite Cognitive Test Score
Ayutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A., Friesenhahn, M. J., Ward, M. E., Aguirre, C., Acosta‐Baena, N., Madrigal, L., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08927 · Cited by 78 · see citing works
Self-citation
Cognitive changes in the preclinical phase of familial Alzheimer's disease
Arango‐Lasprilla, J. C., Cuetos, F., Valencia, C., Uribe, C., & Lopera, F. J. (2007) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390601174151 · Cited by 41 · see citing works
Self-citation
Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials
Weninger, S. C., Carrillo, M. C., Dunn, B., Aisen, P. S. S., Bateman, R. J., Kotz, J., Langbaum, J. B. S., Mills, S. L., Reiman, E. M., Sperling, R. A., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.04.001 · Cited by 38 · see citing works
Self-citation
List of Drugs in Development for Neurodegenerative Diseases: Update June 2009
Poga&ccaron;i&cacute;, V., & Herrling, P. L. (2009) · Neurodegenerative Diseases · doi:10.1159/000232576 · Cited by 29 · see citing works
Demencia tipo Alzheimer con agregación familiar en Antioquia, Colombia
Restrepo, F. J. L., Burgos, O. M. A., Zapata, L., Kosik, K. H., Ochoa, J. W. C., & Londoño, J. E. O. (1994) · Institutional Repository University of Antioquia (University of Antioquia) · Cited by 23 · see citing works
O4‐11‐06: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
Cummings, J. L., Cho, W., Ward, M. E., Friesenhahn, M. J., Brunstein, F., Honigberg, L. A., Clayton, D., Mortensen, D. L., Ho, C., & Paul, R. H. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.450 · Cited by 21 · see citing works
Self-citation
Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation
Kosik, K. S., Muñoz, C., López, L., Arcila, M. L., García, G., Madrigal, L., Moreno, S., Romenets, S. R., Lopez, H., Gutierrez, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001130 · Cited by 19 · see citing works
Self-citation
Descripción de una familia con demencia presenil tipo Alzheimer
Restrepo, F. J. L., Cornejo, W., Salinas, M. C. R., & Uribe, C. S. (1987) · AMC. Acta médica colombiana · Cited by 16 · see citing works
Raven Progressive Matrices
(2012) · SpringerReference · doi:10.1007/springerreference_183813 · Cited by 12 · see citing works
List of Drugs in Development for Neurodegenerative Diseases: Update June 2010
Kramp, V. P., & Herrling, P. L. (2010) · Neurodegenerative Diseases · doi:10.1159/000318238 · Cited by 8 · see citing works
P3‐287: Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects: Findings in the Colombian kindred with the E280A Presenilin 1 mutation and the Alzheimer's Prevention Initiative
Ayutyanont, N., Lopera, F. J., Hendrix, S. B., Langbaum, J. B. S., Madrigal, L., Moreno, S., Tirado, V., Muñoz, C., Henao, E., Ruiz‐Rizzo, A. L., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1729 · Cited by 2 · see citing works
Self-citation
IC‐P‐098: Reduced regional gray matter in cognitively normal young adults at genetic risk for early‐onset Alzheimer's disease
Fleisher, A., Quiroz, Y. T., Chen, K., Langbaum, J. B. S., Thiyyagura, P., Liu, X., Lee, W., Roontiva, A., Ruiz‐Rizzo, A. L., Tariot, P. N., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.063 · Cited by 1 · see citing works
Self-citation
P1‐337: Task‐dependent fMRI abnormalities in young adults at genetic risk for early‐onset Alzheimer's disease
Quiroz, Y. T., Sperling, R. A., Lopera, F. J., Fleisher, A., Chen, K., Tirado, V., Muñoz, C., Langbaum, J. B. S., Tariot, P. N., Stern, C. E., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.617 · Cited by 1 · see citing works
Self-citation
O1‐04‐06: Elevated cerebrospinal fluid amyloid‐Beta42 levels in young adults at genetic risk for early‐onset alzheimer's disease
Reiman, E. M., Velez‐Pardo, C., del Rio, M. J., Giraldo, M., Acosta‐Baena, N., Kosik, K. S., Shah, A. R., Quiroz, Y. T., Chen, K., Fagan, A. M., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.253 · Cited by 1 · see citing works
Self-citation
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Self-citation

Flagged first, then by citations

Sorted by citations

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · see citing works
Self-citation
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965 · see citing works
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988 · see citing works
“In 2012, DIAN-TU launched the first prevention trial focusing on two drugs: gantenerumab (against Aβ aggregates) and solanezumab (against soluble Aβ monomers).337 The data showed that gantenerumab had a positive impact on the reduction of cortical amyloid, leading to its further study by an exploratory open-label exte…”
Background
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557 · see citing works
Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 271 · see citing works
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197 · see citing works
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak-Vance, M., Foroud, T., & Mayeux, R. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 143 · see citing works
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study
Quiroz, Y. T., Zetterberg, H., Reiman, E. M., Chen, Y., Su, Y., Fox-Fuller, J. T., Garcia, G., Villegas, A., Sepulveda-Falla, D., Villada, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30137-x · Cited by 159 · see citing works
Self-citation
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147 · see citing works
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 142 · see citing works
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130 · see citing works
Self-citation
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, M. G., Wuu, J., McHutchison, C. A., Postuma, R. B., Boeve, B. F., Petersen, R. C., Ross, C. A., Rosen, H. J., Arias, J. J., Fradette, S., et al. (2021) · Brain · doi:10.1093/brain/awab404 · Cited by 118 · see citing works
Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia
Bassil, R., Shields, K., Granger, K., Zein, I., Ng, S., & Chih, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25344-6 · Cited by 106 · see citing works
The Alzheimer’s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116 · see citing works
Self-citation
Clinical application of next-generation sequencing to the practice of neurology
Rexach, J. E., Lee, H.-N., Martinez-Agosto, J., Nemeth, A., & Fogel, B. (2019) · Lancet Neurology · doi:10.1016/s1474-4422(19)30033-x · Cited by 101 · see citing works
Immunotherapies for Neurodegenerative Diseases
Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 112 · see citing works
Age at onset in genetic prion disease and the design of preventive clinical trials
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007745 · Cited by 103 · see citing works
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102 · see citing works
Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98 · see citing works
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 93 · see citing works
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 92 · see citing works
Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status
Kaplow, J., Vandijck, M., Gray, J., Kanekiyo, M., Huyck, E., Traynham, C. J., Esquivel, R., Fagan, A. M., & Luthman, J. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12000 · Cited by 81 · see citing works
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease
Jutten, R. J., Papp, K. V., Hendrix, S. B., Ellison, N., Langbaum, J. B. S., Donohue, M., Hassenstab, J. J., Maruff, P. T., Rentz, D. M., Harrison, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12773 · Cited by 79 · see citing works
Self-citation
Individualized clinical management of patients at risk for Alzheimer's dementia
Isaacson, R., Hristov, H., Saif, N., Hackett, K., Hendrix, S. B., Melendez, J., Safdieh, J. E., Fink, M. E., Thambisetty, M., Sadek, G., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.08.198 · Cited by 75 · see citing works
Self-citation
Meaningful benefits: A framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71 · see citing works
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 72 · see citing works
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
Kim, S. Y. H., Karlawish, J. H., & Berkman, B. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001451 · Cited by 70 · see citing works
Tau immunotherapies for Alzheimer’s disease
Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y. M., & Decourt, B. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1619694 · Cited by 68 · see citing works
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Guthrie, H., Honig, L., Lin, H., Sink, K., Blondeau, K., Quartino, A., Dolton, M., Carrasco-Triguero, M., Lian, Q., Bittner, T., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200134 · Cited by 48 · see citing works
Self-citation
Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis
Cacciamani, F., Houot, M., Gagliardi, G. P., Dubois, B., Sikkes, S. A. M., Sánchez‐Benavides, G., Denicolò, E., Molinuevo, J. L., Vannini, P., & Epelbaum, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.697234 · Cited by 63 · see citing works
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62 · see citing works
Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred
(2019) · doi:10.14283/jpad.2019.6 · Cited by 57 · see citing works
Self-citation
Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez‐Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 54 · see citing works
Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 57 · see citing works
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56 · see citing works
Genetic Phenotypes of Alzheimer’s Disease: Mechanisms and Potential Therapy
Quan, M., Cao, S., Wang, Q., Wang, S., & Jia, J. (2023) · Phenomics · doi:10.1007/s43657-023-00098-x · Cited by 60 · see citing works
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54 · see citing works
Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice
Mably, A. J., Liu, W., Donald, J. M. M., Dodart, J., Bard, F., Lemere, C. A., O’Nuallain, B., & Walsh, D. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.008 · Cited by 52 · see citing works
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
Langlois, C. M., Bradbury, A. R., Wood, E. M., Roberts, J. S., Kim, S. Y. H., Riviere, M., Liu, F., Reiman, E. M., Tariot, P. N., Karlawish, J. H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.013 · Cited by 50 · see citing works
Self-citation
Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 53 · see citing works
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
Yoshida, K. J., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H. H., Honigberg, L. A., Jin, J. Y., & Quartino, A. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48 · see citing works
Self-citation
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47 · see citing works
Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease
Vannini, P., Hanseeuw, B. J., Gatchel, J. R., Sikkes, S. A. M., Alzate, D., Zuluaga, Y., Moreno, S., Méndez, L., Baena, A. Y., Ospina-Lopera, P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.27472 · Cited by 44 · see citing works
Self-citation
Alzheimer’s Disease: Drug Discovery
Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 45 · see citing works
Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia
Xiong, C., Luo, J. R., Coble, D. W., Agboola, F., Kukull, W. A., & Morris, J. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12060 · Cited by 42 · see citing works
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40 · see citing works
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40 · see citing works
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40 · see citing works
Self-citation
Coauthor Country Affiliations in International Collaborative Research Funded by the US National Institutes of Health, 2009 to 2017
Grubbs, J. C., Glass, R. I., & Kilmarx, P. H. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.15989 · Cited by 39 · see citing works
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 38 · see citing works
What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40 · see citing works
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36 · see citing works
N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 36 · see citing works
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37 · see citing works
New Insights into the Molecular Bases of Familial Alzheimer’s Disease
D’Argenio, V., & Sarnataro, D. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020026 · Cited by 35 · see citing works
Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
Mortberg, M. A., Vallabh, S. M., & Minikel, E. V. (2022) · Scientific Reports · doi:10.1038/s41598-022-21820-1 · Cited by 33 · see citing works
Early diagnosis and targeted treatment strategy for improved therapeutic outcomes in Alzheimer’s disease
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34 · see citing works
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
Ríos‐Romenets, S., Lopera, F. J., Sink, K. M., Hu, N., Lian, Q., Guthrie, H., Smith, J. P., Cho, W., Mackey, H. M., Langbaum, J. B. S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12109 · Cited by 31 · see citing works
Self-citation
Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations
Pimenova, A. A., & Goate, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104785 · Cited by 30 · see citing works
Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes
Llibre‐Guerra, J. J., Li, Y., Allegri, R., Méndez, P. C., Surace, E. I., Rodríguez, J. J. L., Sosa, A. L., Aláez‐Verson, C., Longoria-Ibarrola, E. M., Téllez‐Martínez, J. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12227 · Cited by 29 · see citing works
Self-citation
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 32 · see citing works
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer’s prevention initiative registry
Torres, V. L., Vila-Castelar, C., Bocanegra, Y., Baena, A., Guzmán-Vélez, E., Aguirre-Acevedo, D. C., Tirado, V., Munoz, C., Henao, E., Moreno, S., et al. (2021) · Applied Neuropsychology: Adult · doi:10.1080/23279095.2019.1627357 · Cited by 28 · see citing works
Self-citation
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
Ghisays, V., Lopera, F. J., Goradia, D. D., Protas, H. D., Malek‐Ahmadi, M. H., Chen, Y., Devadas, V., Luo, J., Lee, W., Baena, A. Y., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102749 · Cited by 28 · see citing works
Self-citation
Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28 · see citing works
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30 · see citing works
Alzheimer Disease Clinical Trials Targeting Amyloid
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 27 · see citing works
Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial
Vila‐Castelar, C., Tariot, P. N., Sink, K. M., Clayton, D., Langbaum, J. B. S., Thomas, R. G., Chen, Y., Su, Y., Chen, K., Hu, N., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12552 · Cited by 27 · see citing works
Self-citation
Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer’s disease
Quan, M., Zhao, T., Tang, Y., Luo, P., Wang, W., Qin, Q., Li, T., Wang, Q., Fang, J., & Jia, J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0572-2 · Cited by 24 · see citing works
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS
Leoutsakos, J., Gross, A. L., Jones, R. N., Albert, M., & Breitner, J. C. S. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.120 · Cited by 22 · see citing works
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 23 · see citing works
The pathway to secondary prevention of Alzheimer's disease
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12069 · Cited by 20 · see citing works
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19 · see citing works
(−)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer’s Disease PSEN1 E280A
Soto‐Mercado, V., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2021) · Biomolecules · doi:10.3390/biom11121845 · Cited by 18 · see citing works
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 18 · see citing works
Früherkennung der Alzheimer-Krankheit und Ansätze der Prävention
Jessen, F. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02877-2 · Cited by 17 · see citing works
Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease
Tatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 16 · see citing works
Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer’s Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor
Soto‐Mercado, V., Mendivil‐Perez, M., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201045 · Cited by 18 · see citing works
Power and sample size for random coefficient regression models in randomized experiments with monotone missing data
Hu, N., Mackey, H. M., & Thomas, R. G. (2021) · Biometrical Journal · doi:10.1002/bimj.202000184 · Cited by 16 · see citing works
Self-citation
Olfactory Function and Markers of Brain Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer’s Disease
Ramirez-Gomez, L. A., Albers, M. W., Baena, A. Y., Vila‐Castelar, C., Fox‐Fuller, J. T., Sanchez, J. S., Jain, F. A., Albers, A. D., Lopera, F. J., & Quiroz, Y. T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220075 · Cited by 15 · see citing works
Self-citation
Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 16 · see citing works
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 15 · see citing works
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial
Reiman, E. M., Pruzin, J. J., Ríos‐Romenets, S., Brown, C., Giraldo, M., Acosta‐Baena, N., Tobón, C., Hu, N., Chen, Y., Ghisays, V., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12843 · Cited by 13 · see citing works
Self-citation
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 13 · see citing works
Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer’s Disease
Alanazy, M. H., Alghsoon, K. A., Alkhodairi, A. F., Binkhonain, F. K., Alsehli, T. N., Altukhaim, F., Alkhodair, I. M., & Muayqil, T. A. (2019) · Neurology Research International · doi:10.1155/2019/2570513 · Cited by 12 · see citing works
Neuroprotective Effect of Combined Treatment with Epigallocatechin 3-Gallate and Melatonin on Familial Alzheimer’s Disease PSEN1 E280A Cerebral Spheroids Derived from Menstrual Mesenchymal Stromal Cells
Soto‐Mercado, V., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220903 · Cited by 12 · see citing works
PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent
Mendivil‐Perez, M., Velez‐Pardo, C., Lopera, F. J., Kosik, K. S., & Jiménez-Del-Río, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108957 · Cited by 11 · see citing works
Self-citation
Who funds Alzheimer's disease drug development?
Cummings, J. L., Bauzon, J. S., & Lee, G. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12185 · Cited by 10 · see citing works
Association Between Visual Memory andIn VivoAmyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer’s Disease
Bocanegra, Y., Fox‐Fuller, J. T., Baena, A. Y., Guzmán‐Vélez, E., Vila‐Castelar, C., Martinez, J. E., Torrico‐Teave, H., Lopera, F. J., & Quiroz, Y. T. (2020) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617720000673 · Cited by 10 · see citing works
Self-citation
Amyloid-Directed Antibodies: Past, Present, and Future
Noorda, K., Noorda, K. J., Sabbagh, M. N., Bertelson, J. A., Singer, J., & Decourt, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240189 · Cited by 9 · see citing works
Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials
Imbimbo, B. P., Triaca, V., Imbimbo, C., & Nisticò, R. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.363185 · Cited by 9 · see citing works
What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium
Kreiner, G. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.006 · Cited by 9 · see citing works
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
Ríos‐Romenets, S., Acosta‐Baena, N., López, L., Madrigal-Zapata, L., Street, H., Jakimovich, L. J., Langbaum, J. B. S., Cho, W., Reiman, E. M., Tariot, P. N., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.010 · Cited by 9 · see citing works
Self-citation
Age of onset in genetic prion disease and the design of preventive clinical trialsPreprint
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/401406 · Cited by 9 · see citing works
Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers
Guzmán‐Vélez, E., Martinez, J. E., Papp, K. V., Baena, A. Y., Vila‐Castelar, C., Artola, A., Schultz, A. P., Bocanegra, Y., Sanchez, J. S., Rentz, D. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010177 · Cited by 8 · see citing works
Self-citation
Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis
Doğan, M., Eröz, R., Tecellioğlu, M., Gezdirici, A., Çevik, B., & Barış, İ. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220414101251 · Cited by 7 · see citing works
Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology
Gomez-Sequeda, N., Mendivil‐Perez, M., Jiménez-Del-Río, M., Lopera, F. J., & Velez‐Pardo, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-39630-4 · Cited by 7 · see citing works
Self-citation
Contribution of extracerebral tracer retention and partial volume effects to sex differences in Flortaucipir-PET signal
Scott, M. R., Edwards, N. C., Properzi, M. J., Jacobs, H. I. L., Price, J. C., Lois, C., Farrell, M. E., Hanseeuw, B. J., Thibault, E. G., Rentz, D. M., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231196978 · Cited by 7 · see citing works
Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer’s disease
Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 6 · see citing works

API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
Sink, K. M., Doody, R. S., Ríos‐Romenets, S., Tariot, P. N., Reiman, E. M., & Langbaum, J. B. S. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.069724 · Cited by 2 · see citing works
Self-citation
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Tariot, P. N., Lopera, F. J., Ríos‐Romenets, S., Sink, K. M., Giraldo, M., Acosta‐Baena, N., Villegas, G., Espinosa, A. C., Castaño, M. L., Muñoz, C. G., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00426-0 · Cited by 4 · see citing works
Self-citation
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia Trial
Bittner, T., Lopera, F. J., Ríos‐Romenets, S., Schiffman, C., Clayton, D., Hibar, D. P., Kollmorgen, G., Dolton, M., Poon, V., Nguyen, J., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106390
Self-citation
The experience acquired during the first prevention clinical trial in Alzheimer's disease in Colombia
Ríos‐Romenets, S., Castaño, M. L., Villegas, G., Muñoz, C., Duque, S. F. L., Cardona, E., Luna, E., Lopez, H., López, L., Valencia, Y., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.121444
Self-citation
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
Ríos‐Romenets, S., Lopera, F. J., Sink, K. M., Hu, N., Lian, Q., Guthrie, H., Smith, J. P., Cho, W., Mackey, H. M., Langbaum, J. B. S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12109 · Cited by 31 · see citing works
Self-citation

Authors: Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., Ramos, C., Espinosa, A., Cho, W., Ward, M., Clayton, D., Friesenhahn, M., Mackey, H., Honigberg, L., Sanabria Bohorquez, S., Chen, K., Walsh, T., Langlois, C., Reiman, E. M., & Initiative, A. P.
Affiliations: Banner Alzheimer’s Institute (US)
Universidad de Antioquia (CO)
University of California San Diego (US)
Pentara Corporation Salt Lake City UT USA
University of Southern California (US)
Grupo de Neurociencias Universidad de Antioquia, SIU Medellín Colombia
Genentech, a Member of the Roche Group South San Francisco CA USA
Genentech (US)
Corresponding author: Tariot, Pierre N.
ORCID: Tariot, Pierre N.
Lopera, Francisco
Langbaum, Jessica B.
Thomas, Ronald G.
Hendrix, Suzanne
Schneider, Lon S.
Giraldo, Margarita
Ward, Michael
Clayton, David
Honigberg, Lee
Chen, Kewei
Reiman, Eric M.
Venue: Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher: Wiley
Published: 2018-01
Volume: 4
Issue: 1
Pages: 150-160
ISSN: 2352-8737 (ISSN-L)
DOI: 10.1016/j.trci.2018.02.002
PMC: PMC6021543
OpenAlex: W2789516300
Cited by: 128
References: 65
Citations by year: 2026: 1 · 2025: 9 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 32 · 2019: 20 · 2018: 7 · 2017: 1 · 2016: 2 · 2015: 2
FWCI: 13.31
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 66 d)
Locations: Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Repositorio Digital - Academia Colombiana de Ciencias Exactas, Fisicas y Naturales (submittedVersion, other-oa)
Funders: National Institute on Aging (1RFAG041705‐01A1)
NOMIS Stiftung
Flinn Foundation (1862)
AstraZeneca
H. Lundbeck A/S
Merck
Roche
Amgen
Biogen
Elan
GE Healthcare
Genentech
Novartis
Arizona Department of Health Services
Foundation for Biomedical Research and Innovation
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords: autosomal dominant Alzheimer's disease, crenezumab, preclinical Alzheimer's disease, PSEN1 E280A mutation, amyloid-beta oligomers, anti-amyloid monoclonal antibodies, cognitive decline prevention, amyloid PET, cerebrospinal fluid biomarkers, tau protein, familial kindred, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review